Roberto Ezequiel Heymann

Consenso brasileiro do tratamento da fibromialgia

Recebido em 06/10/2009. Aprovado, apos revisao, em 24/11/2009. Roberto Ezequiel Heymann e Eduardo dos Santos Paiva declaram ter recebido honorarios da Lilly, Janssen-Cilag, Boehringer, Apsen e Pfizer para palestras e consultoria; Milton Helfenstein Junior recebeu honorarios da Pfizer e Merck Sharp para palestras e consultoria; Daniel Feldman Pollak recebeu honorarios da Lilly, Pfizer e Merck Sharp; Jose Eduardo Martinez recebeu honorarios da Sanofi Aventis para palestras e da Pfizer para palestras e consultoria; Jose Roberto Provenza recebeu honorarios dos laboratorios Roche, Bristol, Ache e Pfizer para participar de pesquisas clinicas com novos farmacos na PUC-Campinas; Marcelo Cruz Rezende declara ter recebido honorarios da Lilly-Boehringer para a participacao em simposios e da Pfizer para ser palestrante e participar de simposios; valerio valim Cristo declara recebimento de honorarios por apresentacao, conferencia ou palestra pela Roche, alem de financiamento para a realizacao de pesquisa, organizacao de atividade de ensino ou comparecimento a simposios pela Lilly, Genzyme, Schering-Plough. os demais autores declararam nao haver conflitos de interesse.1. Coordenador do Ambulatorio de Fibromialgia da UNiFESP e assistente doutor da Disciplina de Reumatologia da UNiFESP2. Professor Assistente da Disciplina de Reumatologia, UFPR. Chefe do ambulatorio de fibromialgia do HC-UFPR3. Assistente doutor da Disciplina de Reumatologia da UNiFESP4. Professor Adjunto da Disciplina de Reumatologia da UNiFESP e chefe do Setor de reumatismos de partes moles da UNiFESP5. Professor titular do Departamento de Medicina da PUC-SP, doutor em Reumatologia pela UNiFESP e diretor da Faculdade de Medicina da PUC-SP6. Professor titular de Reumatologia da PUC-Campinas e chefe do Servico de Reumatologia do Hospital Universitario da PUC-Campinas7. Professora orientadora da pos-graduacao da Faculdade de Ciencias da Saude da UnB e chefe do centro de ambulatorios do Hospital Universitario de Brasilia8. Membro da Sociedade Brasileira de Reumatologia9. Mestre em Medicina pelo instituto de Ensino e Pesquisa da Santa Casa de Belo Horizonte, coordenador do Programa de Residencia Medica em Reumatologia e do Ambulatorio de Fibromialgia da Santa Casa de Belo Horizonte10. Ex-presidente da Sociedade Brasileira de Reumatologia, bienio 2007-200811. Professora colaboradora da Faculdade de Medicina da USP, assistente doutora do Servico de Reumatologia e responsavel pelo ambulatorio de Fibromialgia do Servico de Reumatologia do HC-FMUSP12. Responsavel pelo Setor de Reumatologia e Preceptor do programa de Residencia em Clinica Medica da Santa Casa de Campo Grande. Ex-presidente da Sociedade de Reumatologia do Mato Grosso do Sul13. Professor assistente de Reumatologia da Universidade Federal de Ciencias da Saude de Porto Alegre (UFCSPA) e mestre em Clinica Medica pela UFGRS14. Reumatologista com especializacao em Medicina Esportiva do setor de reabilitacao, procedimentos e coluna vertebral pela UNiFESP15. Ex-fellow da Universidade da virginia (EUA), mestre em Educacao e Ciencia e professora da UNiSUL16. Professora adjunto do Departamento de Clinica Medica, chefe do ambulatorio de fibromialgia e chefe do servico de Reumatologia do Hospital Universi-tario da Universidade Federal do Espirito Santo17. Doutora em Reumatologia pela UNiFESP, membro da Sociedade Brasileira de Reumatologia e da Sociedade Brasileira de Clinica Medica18. Membro da Sociedade Brasileira para o Estudo da Dor19. Presidente da Associacao Brasileira de Medicina Fisica e Reabilitacao, professora colaboradora da Faculdade de Medicina da Universidade de Sao Paulo e doutora em Medicina pela FMUSP20. Membro da Associacao Brasileira de Medicina Fisica e Reabilitacao21. Professor titular de Neurologia da Universidade Federal Fluminense (UFF), coordenador do Departamento de Dor da Academia Brasileira de Neurologia (ABN) e do Subcomite de Dor da European Neurological Society (ENS). Membro da Peripheral Nerve Society22. Doutor em ortopedia e Traumatologia pela Faculdade de Medicina da USP, medico Assistente do Grupo de Mao e professor colaborador da FMUSP23. Membro da Sociedade Brasileira de ortopedia e Traumatologia24. Membro da Consultoria Axia.Bio farmacoeconomia e pesquisa em saude25. Diretor executivo do Nucleo de Gestao de Pesquisas da UNiFESP, mestre em Ciencias pela UNiFESP e socio-pesquisador da Axia.Bio

A comparison of quality of life, demographic and clinical characteristics of Brazilian men with fibromyalgia syndrome with male patients with depression.

The primary aim of this study was to assess the quality of life (Qol) in men with fibromyalgia (FM) as compared to the Qol of depressive patients, using the SF-36 questionnaire. The secondary objectives were as follows: to describe demographic and clinical characteristics of male patients with FM; to evaluate basal levels of dehydroepiandrosterone sulfate (DHEAS) and total testosterone in both groups; and to investigate the relationship among pain, tender points, anxiety, and depression in these patients. Fifty men with FM and 20 depressed males, matched by age and body mass index entered the study. All participants answered the SF-36, the Beck Depression Inventory and the State-Trait Anxiety Inventory questionnaire. Radioimmunoassay was used to determine serum concentration of DHEAS and total testosterone. Patients and controls had similar demographic characteristics. The scores were significantly lower in all domains of the SF-36 in patients with FM as compared with the depressive controls. No significant differences were observed among patient and control in the mean concentration of either DHEAS or total testosterone. Male patients with FM experience worse Qol than depressive men. Depression was influential on mental health, whereas FM impacted on both physical and mental health.

EpiFibro - um banco de dados nacional sobre a síndrome da fibromialgia: análise inicial de 500 mulheres

INTRODUCAO: A fibromialgia (FM) e uma condicao dolorosa do sistema musculoesqueletico, geralmente acompanhada de varios sintomas em outros sistemas, com uma prevalencia no Brasil estimada em 2,5%. Apresentamos os dados iniciais do EpiFibro, um banco de dados nacional de pacientes com FM atendidos em servicos publicos e privados. OBJETIVO: Avaliar como e feito o diagnostico da doenca, identificar um conjunto de dominios clinicos considerados relevantes por medicos e por pacientes com FM, analisar o impacto da doenca na qualidade de vida dos pacientes e comparar os achados entre pacientes de servicos publico e privado. METODOS: Foram analisadas as respostas das primeiras 500 mulheres nesse banco de dados. Esse banco de dados foi baseado em um questionario contendo dados demograficos e clinicos. O Fibromyalgia Impact Questionnaire (FIQ), traduzido e validado para o Brasil, foi preenchido pelos medicos e/ou pacientes. RESULTADOS: Uma analise preliminar do banco de dados EpiFibro revelou que as pacientes com FM no Brasil tem um alto impacto da doenca avaliada pelo FIQ, uma alta prevalencia de sintomas associados, um baixo grau de educacao (um achado que pode ser explicado pelo fato de a saude publica no Brasil ser usada principalmente por aqueles desfavorecidos socialmente) e a maioria percebe a sua dor como sendo difusa a partir do inicio da doenca. CONCLUSAO: Depressao e ansiedade sao percebidas como as principais causas dos sintomas da FM, mas uma quantidade significativa considera o esforco no trabalho como o primeiro gatilho. Ha um atraso de poucos anos em busca de ajuda medica e para chegar ao reumatologista.

A Brazilian Portuguese version of the Revised Fibromyalgia Impact Questionnaire (FIQR): a validation study

The Fibromyalgia Impact Questionnaire (FIQ) was specifically developed to assess disease severity and functional ability in fibromyalgia patients. In 2009, a revised version of the FIQ was published, the FIQR; this version achieved a better balance among different domains (function, overall impact, symptoms). Here, we present the validity and reliability of the Brazilian version of the Revised Fibromyalgia Impact Questionnaire (FIQR). Female fibromyalgia patients (n = 106) completed an online survey consisting of the Short Form 36 (SF-36) questionnaire, the original FIQ, and the Brazilian Portuguese FIQR, which was translated by a standard method. Validity was established with correlational analyses between the FIQR, FIQ, and SF-36 items. Three domains were established for the FIQR (function, overall impact, symptoms), and their contribution for the SF-36 subscales was also scrutinized. The Brazilian FIQR validation process showed that the questions performed in a very similar way to the original English FIQR. The new questions in the FIQR symptoms domain (memory, balance, tenderness, and environmental sensitivity) revealed a significant impact in fibromyalgia (FM) patients. The Brazilian Portuguese FIQR demonstrated excellent reliability, with a Cronbach’s alpha of 0.96. There was a gain on weight of the function domain and a decrease of the symptom domain, leading to a better balance among domains. The FIQR predicted a great number of SF-36 subscales, showing good convergent validity. The Brazilian Portuguese version of the FIQR was validated and found to be a reliable, easy-to-use, and score FM-specific questionnaire that should prove useful in routine clinical practice and FM-related research.

EpiFibro – a nationwide databank for fibromyalgia syndrome – the initial analysis of 500 women

INTRODUCTION Fibromyalgia syndrome (FS) is a common painful condition of the musculoskeletal system that is typically accompanied by several symptoms in other systems. In Brazil, the prevalence of FS is estimated at 2.5%. Here, we present the initial data from Epi-Fibro, a nationwide databank of FS patients seen in public and private settings. OBJECTIVE The aims of this study were to assess how the diagnosis of FS was made, identify a set of clinical domains considered relevant by both clinicians and patients in cases of FS, analyse the impact of disease on patient quality of life, and compare the findings among patients of public and private services. METHODS Based on the results of questionnaires, we analysed data corresponding to the first 500 women in the database. Questionnaires pertaining to demographic and clinical data and the Fibromyalgia Impact Questionnaire (FIQ), which was translated and validated for Brazilian patients, were completed by the clinicians and/or patients. RESULTS Preliminary analysis of the EpiFibro databank revealed that female FS patients in Brazil reported a high impact of disease, as measured by the FIQ, a high prevalence of associated symptoms, and a low degree of education (consistent with the public health care in Brazil used mainly by the underserved). In addition, most patients perceived their pain as diffuse from the onset of disease. CONCLUSION Depression and anxiety were seen as the main triggers of FM symptoms, but a significant proportion of the subjects perceived work strain as the initial trigger.We also observed a delay of a few years in seeking medical help and examination by a rheumatologist.

Prevalência da síndrome do cólon irritável em pacientes com fibromialgia

INTRODUCTION: Fibromyalgia is a prevalent syndrome of widespread pain and multiple tender points, with no inflammatory, dystrophic or degenerative changes, probably related to abnormal central modulation of pain processing. Irritable bowel syndrome is considered a dysfunctional syndrome of visceral pain and/or alteration on gastrointestinal motility, also related to the same central nervous system (CNS) abnormalities. OBJECTIVE: The aim of this study was to evaluate the prevalence of irritable bowel syndrome in patients with fibromyalgia and to establish their clinical characteristics. PATIENTS AND METHODS:Two hundred consecutive patients with fibromyalgia syndrome were studied. RESULTS: These, 134 (67%) had irritable bowel syndrome. The most common presentation was the constipation subtype (121 =90.2%). The majority of patients had high scores of anxiety and/or depression. Conclusion: No differences were noted among patients with fibromyalgia without irritable bowel syndrome, and those with both conditions.

New guidelines for the diagnosis of fibromyalgia

OBJECTIVE To establish guidelines based on scientific evidence for the diagnosis of fibromyalgia. MATERIAL AND METHODS Evidence collection was performed based on 9 questions regarding the diagnosis of fibromyalgia, structured using the Patient, Intervention or Indicator, Comparison and Outcome (P.I.C.O.), with searches in the main, primary databases of scientific information. After defining the potential studies to support the recommendations, they were graded according to evidence and degree of recommendation.

And the history goes on.

n the editorial of August 2013, RBR celebrated the publication f the first impact factor (IF) of 0.864, measured by the Journal f Citation Reports (JCR), ranking RBR among the 12 national ndexed journals. At the time, we defined as our main goal to each an IF figure of 1.0. In 2014 we almost got there, with the ark of 0.993, and this outcome corroborated the feasibility of ur goal and signaled that we were right on track. Our focus as maintained, and this year we can proudly announce that ur dedication over the years of existence of RBR has overcome nother historical level – in the last issue of the JCR our IF was ,087. We are now among the 10 national magazines of greater mpact, ranking among 24 international publications in the rea and we are the first in the rheumatology subject in Latin merica. ‘Are we pleased? Of course not! Despite all this success, e know that there is a lot to be done yet. Therefore, we are ostering a series of changes involving the professionalization f our work, with a reclassification of submitted manuscripts, greater number of reviewers, and a greater control of the eview flow – measures already resulting in a significant eduction in our review deadlines and in the final decision n submitted manuscripts. We have also established even stronger requirements for the acceptance of manuscripts; with this strategy, we aim to increase the scientific level of our journal, according to its profile and new level of excellence. We intend not only to achieve a higher IF, but in the near future, we intend also to consolidate internationally RBR among the main rheumatologic publications. We also planned other changes with the help of several collaborators linked to the editorial staff. Such changes will take place gradually, with the goal of improving the quality and dissemination of RBR, and also aiming to expand the experience of authors and readers. We rely on everyone’s help.

Care against infections in rheumatic autoimmune diseases

Corresponding author. E-mail: a.assismr@gmail.com (M.R. Assis). 2255-5021/© 2015 Elsevier Editora Ltda. All rights reserved. http://dx.doi.org/10.1016/j.rbre.2015.06.001 n this issue we have two articles of great interest to the clincal practice of Rheumatology as well as other specialties. esigned primarily for members of the Commissions of Epiemiology and Rheumatoid Arthritis of the Brazilian Society f Rheumatology (SBR), they present a consensus of specialists ased on a literature review. The first article is a review of Braz et al.1 on the treatment f intestinal parasites in patients with autoimmune rheumatic iseases, which addresses the situations of immunosuppresion risk often experienced. This is an article that discusses a opic that has not received due importance, both in scientific edia and in the daily practice of rheumatologists, who strive o prevent viral and bacterial infections and tuberculosis, often eglecting parasitic infections. Perhaps this occurs in face of he shortage of reports of serious infections by these agents. n the other hand, the authors comment on the high morbidty and mortality of such infections in this population, which erves as a basis for prescribing treatment and prophylactic rug interventions. The second article is a positioning from Mota et al.2 in ace of the unavailability of the tuberculin skin test (PPD), the ecommended tool in the evaluation and treatment of latent uberculosis in patients with rheumatoid arthritis. The lack of eagent for the test, reported by the Ministry of Health, has rought growing impact from the second half of 2014, causing oncern both for physicians and patients and also delays in the rescribing and dispensing of biologicals, as well as prescripions without the recommended care. Here the authors show ow the physician should proceed in this context and highight the importance of provision of interferon gamma release ssays, tests known as IGRA (interferonrelease assays), to